This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Genzyme’s Multiple Sclerosis Franchise Featured At AAN

Genzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY), announced today that data from its AUBAGIO ® (teriflunomide) and LEMTRADA TM (alemtuzumab) multiple sclerosis clinical development programs will be presented during the 65 th American Academy of Neurology (AAN) Annual Meeting to be held in San Diego, Calif., March 16-23.

We are proud to present these results that offer important new insights into AUBAGIO and LEMTRADA,” said Genzyme CEO and President, David Meeker, MD. “ Our robust clinical development programs underscore our steadfast commitment to advancing our understanding of multiple sclerosis and its treatment, and to providing new hope for people living with this devastating disease.

Data from across the company’s clinical development programs to be presented at AAN during Pacific Time are as follows, along with details about the Genzyme Corporate Therapeutic Update and Brain Health Fair sponsorship.

Platform Presentations for AUBAGIO and LEMTRADA:

AUBAGIO:

  • Pre-Defined Subgroups Analyses of TOWER, a Placebo‐Controlled Phase 3 Trial of Teriflunomide in Patients with Relapsing Multiple Sclerosis (Platform Presentation Session 41 – S41.006; March 21; 1:30 p.m.)
  • Teriflunomide Efficacy and Safety in Patients with Relapsing Multiple Sclerosis: Results From TOWER, a Second, Pivotal, Phase 3 Placebo‐Controlled Study (Platform Presentation Session 1 – S01.004; March 19; 1:45 p.m.)
  • Pregnancy Outcomes From the Teriflunomide Clinical Development Program: Retrospective Analysis of the Teriflunomide Clinical Trial Database (Platform Presentation Session 30 – S30.005; March 20; 3:00 p.m.)

LEMTRADA:

  • Durable Efficacy of Alemtuzumab in Relapsing‐Remitting Multiple Sclerosis Patients Who Participated in the CARE‐MS Studies: Three Year Follow‐Up (Platform Presentation Session 41 – S41.001; March 21; 12:00 p.m.)

Additional Presentations:

AUBAGIO:

Poster Presentations

  • Immune Response to Seasonal Influenza Vaccination in Patients with Relapsing Multiple Sclerosis Treated with Teriflunomide: the TERIVA Study (Poster Session I – P01.169; March 18; 2:00 p.m.)
  • Frequency of Infections During Treatment with Teriflunomide: Pooled Data From Three Placebo‐Controlled Teriflunomide Studies (Poster Session I – P01.171; March 18; 2:00 p.m.)
  • Teriflunomide Reduces Relapse‐Related Sequelae, Hospitalizations and Corticosteroid Use: A Post‐Hoc Analysis of the Phase 3 TOWER Study (Poster Session VII – P07.109; March 21; 2:00 p.m.)

LEMTRADA:

Poster Presentations

  • Disability Improvement with Alemtuzumab vs. Interferon beta‐1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE‐MS II) (Poster Session VII – P07.120; March 21; 2:00 p.m.)
  • Efficacy of Alemtuzumab vs IFNB‐1a in Relapsing‐Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE‐MS II): Subgroup Analysis by Previous Disease Modifying Therapy (DMT) Use (Poster Session VII – P07.111; March 21; 2:00 p.m.)
  • Alemtuzumab Reduces MS Disease Activity in Active Relapsing‐Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (Poster Session VII – P07.093; March 21; 2:00 p.m.)
  • Adverse Event Profile of Alemtuzumab Over Time in Active Relapsing‐Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE‐MS II) (Poster Session I – P01.174; March 18; 2:00 p.m.)
  • Detection, Incidence, and Management of Thyroid Autoimmunity in Comparison of Alemtuzumab and Rebif ® in Multiple Sclerosis (CARE‐MS I and II) (Poster Session I – P01.173; March 18; 2:00 p.m.)
  • Comparison of Infection Risk with Alemtuzumab and SC IFNB‐1a in Patients with Multiple Sclerosis Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (Poster Session I – P01.172; March 18; 2:00 p.m.)
  • Anti-IFNB-1a Antibody Status Was Not a Factor Influencing Efficacy of Alemtuzumab vs IFNB-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (Poster Session VII – P07.125; March 21; 2:00 p.m.)
  • Immunogenicity of Alemtuzumab Treatment in Relapsing‐Remitting Multiple Sclerosis (RRMS) Patients in the CARE‐MS II Study (Poster Session VII – P07.101; March 21; 2:00 p.m.)
  • Relapse Outcomes with Alemtuzumab vs IFNB‐1a in Active Relapsing‐Remitting Multiple Sclerosis Patients Who Experienced Disease Activity on Prior Therapy (CARE‐MS II) (Poster Session VII – P07.098; March 21; 2:00 p.m.)

Abstracts are available on the AAN website.

Stock quotes in this article: SAN, SNY 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs